Skip to content
Bored Studies
RecruitingPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Eli Lilly and Company · NCT07668336

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 10–17 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
170
US sites recruiting
12
Study start
July 8, 2026
Record last updated
October 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.

Participation in the study will last about 61 weeks.

Being studied: Orforglipron; Dulaglutide

Conditions: Diabetes Mellitus, Type 2

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
  • Have HbA1c > 6.5% to ≤ 11.0% at screening
  • Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile

Exclusion Criteria

  • Have type 1 diabetes
  • After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
  • Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
  • Have a history of pancreatitis or gallbladder disease
  • Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening
  • Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening

Recruiting US locations

  • Stamford Therapeutics Consortium

    Stamford, CT 06905

    Site contact: David Radin

  • CenExel iResearch, LLC

    Decatur, GA 30030

    Site contact: 4045371281

  • Medical Research Partners

    Ammon, ID 83406

    Site contact: (208) 522-4600

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, KS 66606

    Site contact: 785-354-9591

  • Advantage Clinical Trials

    The Bronx, NY 10467

    Site contact: 917-962-0234

  • Central States Research

    Tulsa, OK 74136

    Site contact: 918-645-5400

  • Frontier Clinical Research, LLC

    Smithfield, PA 15478

    Site contact: 7245698036

  • Gadolin Research

    Beaumont, TX 77702

    Site contact: 409-331-6040

  • Driscoll Children's Hospital

    Corpus Christi, TX 78411

    Site contact: 3617397250

  • Proactive Clinical Research LLC

    Edinburg, TX 78539

    Site contact: 956-731-1260

  • Consano Clinical Research, LLC

    Shavano Park, TX 78231

    Site contact: 210-545-4900

  • Victoria Clinical Research Group

    Victoria, TX 77901

    Site contact: 3612107869

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All diabetes studies in Connecticut →
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in… (NCT07668336) | Bored Studies